8 citations
,
July 2023 in “Frontiers in Pharmacology” This review highlights cepharanthine as a promising candidate for COVID-19 treatment due to its antiviral activity against SARS-CoV-2 and favorable pharmacokinetic and safety profile, but reports no new clinical results.
15 citations
,
July 2022 in “Frontiers in Pharmacology” This study suggests that Cepharanthine, a monomer in traditional Chinese medicine, may help treat COVID-19 by affecting multiple signaling pathways, and that TNF and IL-17 inhibitors used in rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis might also be beneficial.
29 citations
,
November 2021 in “FEBS Open Bio” In this study, molecular docking simulations and cell-based assays suggested that certain analogues of cepharanthine might possess anti-SARS-CoV-2 activity.
In this study, cepharanthine and tetrandrine demonstrated efficacy against SARS-CoV-2 in a cell-based infection assay, with cepharanthine showing a lower IC50 value.
3 citations
,
June 2023 in “Molecules/Molecules online/Molecules annual” The researchers reviewed cepharanthine, a long-used bisbenzylisoquinoline alkaloid, for its antiviral properties, including significant inhibition of SARS-CoV-2. They discussed cepharanthine's other pharmacological actions, highlighted plasma membrane fluidity as a key antiviral mechanism, and examined its safety, bioavailability, and potential for new clinical applications.